OncoCyte Co. (NASDAQ:OCX – Get Free Report) CFO Andrea S. James bought 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 5th. The stock was acquired at an average cost of $2.29 per share, with a total value of $45,800.00. Following the transaction, the chief financial officer now owns 53,670 shares of the company’s stock, valued at $122,904.30. This represents a 59.40 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
OncoCyte Stock Performance
Shares of OCX opened at $2.46 on Tuesday. The company’s fifty day simple moving average is $2.85 and its 200 day simple moving average is $2.95. OncoCyte Co. has a 1-year low of $1.98 and a 1-year high of $3.82.
OncoCyte (NASDAQ:OCX – Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.98) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.54). The firm had revenue of $0.12 million during the quarter. OncoCyte had a negative net margin of 6,122.29% and a negative return on equity of 269.32%. During the same period in the previous year, the business posted ($0.57) earnings per share. Equities analysts forecast that OncoCyte Co. will post -2.57 earnings per share for the current fiscal year.
Hedge Funds Weigh In On OncoCyte
Analyst Ratings Changes
OCX has been the subject of a number of recent research reports. StockNews.com initiated coverage on shares of OncoCyte in a research note on Sunday. They set a “sell” rating for the company. Needham & Company LLC reiterated a “buy” rating and set a $4.25 target price on shares of OncoCyte in a report on Wednesday, November 13th.
Check Out Our Latest Stock Report on OncoCyte
OncoCyte Company Profile
OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.
See Also
- Five stocks we like better than OncoCyte
- What Are Dividend Contenders? Investing in Dividend Contenders
- How to Master Trading Discipline: Overcome Emotional Challenges
- Health Care Stocks Explained: Why You Might Want to Invest
- Does China Investigation Change NVIDIA’s Outlook; Yes, No, Maybe?
- With Risk Tolerance, One Size Does Not Fit All
- Is Marvell Technology Chipping Away at NVIDIA’s Market Lead?
Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.